On August 28th, Zhongkang Holdings (02361.HK) announced that for the six months ended June 30, 2024, benefiting from the continuous expansion of the industry cooperation network, the continuous innovation of products and business, the customer volume and price of smart retail cloud and SaaS products have increased, thereby further boosting the group's revenue scale and operational efficiency. The revenue was approximately RMB 0.16 billion, a year-on-year increase of about 10.1%. Leading big data processing technology and continuous solid data platform construction have greatly improved technological efficiency, thus continuously optimizing the group's cost efficiency and nurturing a higher-quality group profit model. The operating profit increased by about 62.1% year-on-year, excluding the impact of exchange gains and losses. The net profit amounted to approximately RMB 40.1 million, a year-on-year increase of about 23.2%, and the net profit margin (excluding exchange gains and losses) increased by 2.7 percentage points compared to the same period in 2023. The company's customer base has covered major participants in the health industry such as pharmaceutical manufacturers, pharmaceutical retailers, medical institutions, physical examination institutions, and innovative drug companies. The number of enterprise customers is 869, an increase of 3.2% from the 842 in the same period of 2023. Among them, the repeat purchase sales rate of top pharmaceutical and medical device enterprise customers is 99.7%, a 5 percentage point increase from the same period in 2023.